09:15 AM EST - MYND Life Sciences Inc. : Announced it has filed additional provisional patents that utilize various psilocybin analogs to target clinical depression. Major Depressive Disorder is a common and severe illness that is estimated to affect approximately 264 million people globally. MYND has two flagship drugs in the development pipeline; MYND-604 and MYND-778. MYND-604 is the lead candidate being developed as a novel oral dosage to treat MDD and brings much needed innovation to the Selective Serotonin Reuptake Inhibitor market. The MYND-604 provisional patent helps advance the Company's drug development pipeline. The Company anticipates the commencement of clinical trials in Q4 of 2021, or early 2022. MYND Life Sciences Inc.
shares C.MYND are trading unchanged at $2.10.
